415 related articles for article (PubMed ID: 32762294)
1. Classical Hodgkin lymphoma-like post-transplant lymphoproliferative disease after allogeneic stem cell transplantation for primary myelofibrosis is successfully treated with nivolumab: A case report.
Gunes AK; Demir I; Pehlivan M
J Oncol Pharm Pract; 2021 Mar; 27(2):509-512. PubMed ID: 32762294
[TBL] [Abstract][Full Text] [Related]
2. Brentuximab vedotin plus nivolumab as first-line therapy in older or chemotherapy-ineligible patients with Hodgkin lymphoma (ACCRU): a multicentre, single-arm, phase 2 trial.
Cheson BD; Bartlett NL; LaPlant B; Lee HJ; Advani RJ; Christian B; Diefenbach CS; Feldman TA; Ansell SM
Lancet Haematol; 2020 Nov; 7(11):e808-e815. PubMed ID: 33010817
[TBL] [Abstract][Full Text] [Related]
3. Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study.
Younes A; Connors JM; Park SI; Fanale M; O'Meara MM; Hunder NN; Huebner D; Ansell SM
Lancet Oncol; 2013 Dec; 14(13):1348-56. PubMed ID: 24239220
[TBL] [Abstract][Full Text] [Related]
4. Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial.
Straus DJ; Długosz-Danecka M; Connors JM; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Munoz J; Lee HJ; Kim WS; Advani R; Ansell SM; Younes A; Gallamini A; Liu R; Little M; Fenton K; Fanale M; Radford J
Lancet Haematol; 2021 Jun; 8(6):e410-e421. PubMed ID: 34048680
[TBL] [Abstract][Full Text] [Related]
5. Post-transplant lymphoproliferative disorder after paediatric liver transplantation.
Liu Y; Sun LY; Zhu ZJ; Wei L; Qu W; Wang L; Yuan LL; Zeng ZG
Int J Clin Pract; 2021 Apr; 75(4):e13843. PubMed ID: 33222369
[TBL] [Abstract][Full Text] [Related]
6. Successful nivolumab therapy in an allogeneic stem cell transplant child with post-transplant lymphoproliferative disorder.
Kassa C; Reményi P; Sinkó J; Kállay K; Kertész G; Kriván G
Pediatr Transplant; 2018 Dec; 22(8):e13302. PubMed ID: 30345623
[TBL] [Abstract][Full Text] [Related]
7. Successful treatment of Hodgkin lymphoma-like EBV-associated post-transplant lymphoproliferative disorder following allogeneic hematopoietic stem cell transplantation with nivolumab.
Wada F; Kondo T; Nakamura M; Chonabayashi K; Nishikori M; Hishizawa M; Yamashita K; Takaori-Kondo A
Ann Hematol; 2020 Apr; 99(4):887-889. PubMed ID: 32052134
[No Abstract] [Full Text] [Related]
8. Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial.
Diefenbach CS; Hong F; Ambinder RF; Cohen JB; Robertson MJ; David KA; Advani RH; Fenske TS; Barta SK; Palmisiano ND; Svoboda J; Morgan DS; Karmali R; Sharon E; Streicher H; Kahl BS; Ansell SM
Lancet Haematol; 2020 Sep; 7(9):e660-e670. PubMed ID: 32853585
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of first-line treatment options for patients with advanced-stage Hodgkin lymphoma: a modelling study.
Vijenthira A; Chan K; Cheung MC; Prica A
Lancet Haematol; 2020 Feb; 7(2):e146-e156. PubMed ID: 31948928
[TBL] [Abstract][Full Text] [Related]
10. Brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine for nonbulky limited-stage classical Hodgkin lymphoma.
Abramson JS; Arnason JE; LaCasce AS; Redd R; Barnes JA; Sokol L; Joyce R; Avigan D; Neuberg D; Takvorian RW; Hochberg EP; Bello CM
Blood; 2019 Aug; 134(7):606-613. PubMed ID: 31186274
[TBL] [Abstract][Full Text] [Related]
11. Classical Hodgkin lymphoma-type PTLD after solid organ transplantation in children: a report on 17 patients treated according to subsequent GPOH-HD treatment schedules.
Kampers J; Orjuela-Grimm M; Schober T; Schulz TF; Stiefel M; Klein C; Körholz D; Mauz-Körholz C; Kreipe H; Beier R; Maecker-Kolhoff B
Leuk Lymphoma; 2017 Mar; 58(3):633-638. PubMed ID: 27685149
[TBL] [Abstract][Full Text] [Related]
12. Stage IV Classical Hodgkin Lymphoma-type Posttransplant Lymphoproliferative Disorder in a Pediatric Liver Transplant Patient: A Case Report and Review of the Literature.
Choi S; Hong KT; Choi JY; Ahn HY; Ko JS; Suh KS; Park SH; Cheon JE; Shin HY; Kang HJ
J Pediatr Hematol Oncol; 2021 Oct; 43(7):e1015-e1019. PubMed ID: 33769384
[TBL] [Abstract][Full Text] [Related]
13. Advanced stages of classical Hodgkin lymphoma - first-line treatment options.
Mociková H
Klin Onkol; 2021; 34(6):450-454. PubMed ID: 34911330
[TBL] [Abstract][Full Text] [Related]
14. Role of brentuximab vedotin plus sirolimus in the treatment of classical Hodgkin lymphoma type post-transplant lymphoproliferative disorder: a case-based review.
Zhou K; Gong D; Han Y; Huang W
Ann Hematol; 2023 Sep; ():. PubMed ID: 37749317
[TBL] [Abstract][Full Text] [Related]
15. Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study.
Straus DJ; Długosz-Danecka M; Alekseev S; Illés Á; Picardi M; Lech-Maranda E; Feldman T; Smolewski P; Savage KJ; Bartlett NL; Walewski J; Ramchandren R; Zinzani PL; Hutchings M; Connors JM; Radford J; Munoz J; Kim WS; Advani R; Ansell SM; Younes A; Miao H; Liu R; Fenton K; Forero-Torres A; Gallamini A
Blood; 2020 Mar; 135(10):735-742. PubMed ID: 31945149
[TBL] [Abstract][Full Text] [Related]
16. A targeted salvage therapy with Brentuximab vedotin in heavily treated refractory or relapsed pediatric Hodgkin lymphoma patients before and after stem cell transplantation.
Taçyıldız N; Tanyıldız HG; Ünal E; Dinçaslan H; Asarcıklı F; Aksoy BA; Vatansever G; Yavuz G
Turk J Pediatr; 2019; 61(5):671-676. PubMed ID: 32104998
[TBL] [Abstract][Full Text] [Related]
17. Radiotherapy in combination with nivolumab for relapsed/refractory classical Hodgkin lymphoma: About two cases.
de Forceville L; Deau-Fischer B; Franchi P; Arsène-Henry A; Cassou Mounat T; Bouscary D; Kirova YM
Cancer Radiother; 2019 Jun; 23(3):232-239. PubMed ID: 31147173
[TBL] [Abstract][Full Text] [Related]
18. Five-year follow-up of brentuximab vedotin combined with ABVD or AVD for advanced-stage classical Hodgkin lymphoma.
Connors JM; Ansell SM; Fanale M; Park SI; Younes A
Blood; 2017 Sep; 130(11):1375-1377. PubMed ID: 28733323
[No Abstract] [Full Text] [Related]
19. Low dose PD-1 inhibition in relapsed refractory Hodgkin lymphoma after allogeneic stem cell transplant with concomitant active GVHD.
Minson A; Douglas G; Bilmon I; Grigg A
Br J Haematol; 2019 Mar; 184(5):840-844. PubMed ID: 29532918
[No Abstract] [Full Text] [Related]
20. Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial.
Bröckelmann PJ; Goergen H; Keller U; Meissner J; Ordemann R; Halbsguth TV; Sasse S; Sökler M; Kerkhoff A; Mathas S; Hüttmann A; Bormann M; Zimmermann A; Mettler J; Fuchs M; von Tresckow B; Baues C; Rosenwald A; Klapper W; Kobe C; Borchmann P; Engert A
JAMA Oncol; 2020 Jun; 6(6):872-880. PubMed ID: 32352505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
